Exosome Treatment for Skin: What the Science Says, What the Regulators Say, and Why the Gap Between Them Matters

By the Cosmabl Clinical Editorial Team. Medically reviewed by Dr Patrick Shively, Medical Director, AHPRA MED0001794908.

Last reviewed 2026-05-19 • Next review 2027-05-19

Three years ago, “exosome” was a word you would find in a cell-biology textbook. Today it is on the menu at half the regenerative-aesthetics clinics in Sydney, on every other beauty video, and on serum bottles selling for the price of a long weekend away. The pitch is intoxicating: cellular text messages, harvested from stem cells, drizzled over your face after microneedling to coax your skin into repairing itself from the inside out.

There is genuine science underneath the pitch. There is also a yawning gap between that science and the version being sold in clinics, and four separate regulators on three continents have now moved against cosmetic exosome use. The published case-series literature on complications has grown notably in 2024 and 2025; the FDA enforcement record has accelerated; the Australian regulatory position is more restrictive than most consumers realise. This is the article in our education series where the evidence and the regulatory direction of travel point most clearly in the same direction — toward caution.

This piece describes what exosomes actually are, what the published evidence supports and where it falls short, what the documented complications look like in the case-series literature, what Australian and overseas regulators have decided so far, and what to ask before you let anyone put one anywhere near your face.

What exosomes actually are

Strip the marketing away and exosomes are quite simple. They are tiny membrane-bound vesicles, around 30 to 150 nanometres across, that almost every cell in the body releases. Inside them, cells package signalling cargo: proteins, lipids, microRNA. Other cells take them up and respond to the message. Think of them less as cells and more as cellular text messages.

The cosmetic industry became interested because, in the laboratory, exosomes harvested from stem cells appear to nudge other cells toward repair, anti-inflammatory, and growth behaviours. Fibroblasts wake up. Wound-healing markers go up. The signalling, in a petri dish, is real and reproducible — there is a substantial preclinical literature documenting these effects.

The leap the marketing tends to gloss over is the one from “interesting in a petri dish” to “applied to a paying customer’s face on a Tuesday afternoon at AUD 850 a session.” That is a longer leap than the brochures suggest, and the rest of this article is about why.

Why the source of the exosomes matters more than the marketing admits

The buried headline of this whole category is source variability. The word “exosome” on a clinic menu can mean almost anything. The product might be derived from human stem cells, cultured from mesenchymal, adipose, or umbilical-cord lines. It might be platelet-derived. It might come from plants — rose, edelweiss, ginger, grapefruit. It might come from animal sources, including salmon and milk. It might be derived from bacterial culture. All of these are sometimes labelled “exosomes” or “exosome-like” particles in the cosmetic market, and the marketing language often does not distinguish between them.

The biology is not interchangeable. Plant-derived exosome-like particles are stable, generally non-immunogenic, and easier to regulate. They also do not signal to human cells the way human-derived particles might. Human stem-cell exosomes carry the species-specific cargo the early research is most excited about. They also carry the regulatory and provenance issues that the industry tends not to mention prominently. Marketing copy frequently collapses the distinction; the science does not.

The 2024 Journal of the American Academy of Dermatology review by Buzalaf and colleagues, “Exploring the reality of exosomes in dermatology,” makes the practical version of this point clearly. What is in a clinic vial is rarely characterised the way published-trial material is characterised. The published research literature describes exosomes by particle count, size distribution, surface markers, and protein cargo. The product applied at a clinic is more often described by a brand name and a price. Those are not the same level of scrutiny, and the patient considering treatment is entitled to know which version they are buying.

Are exosomes FDA approved?

The answer is genuinely simple: no. Not for cosmetic use. Not for therapeutic use. Not for anything.

The US Food and Drug Administration first put this on the public record in its Public Safety Notification of 6 December 2019, which stated bluntly that there are no approved exosome products and that clinics offering them outside the FDA review process are taking on substantial regulatory risk. The agency reiterated this in its July 2020 Consumer Alert on regenerative medicine products, and again in a sequence of warning letters that have continued through 2024, 2025, and into 2026.

Recent enforcement actions are worth naming because they show the pattern. Exocel Bio received an untitled letter in May 2024. Neobiosis LLC received a warning letter in June 2024. Evolutionary Biologics received a warning letter in late December 2024 for their EXO RNA, EVO JEL, and EVO HYBRID products. Chara Biologics received a warning in early 2025. Supreme Rejuvenation received a warning letter in May 2025 covering “100 Billion Exosomes” products. New Life Medical Services received a further warning letter in September 2025. The FDA reissued and updated its Public Safety Notification on Exosome Products, current as of May 2026, restating the position and explicitly noting that warning letters have been sent to administering physicians and medical providers, not just manufacturers and distributors. The regulatory exposure has moved downstream.

The FDA framing across all of these letters is consistent: exosome products are unapproved new drugs and unlicensed biological products under the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act. There is no pathway in which a clinic in the United States can sell them as a cosmetic or aesthetic treatment without breaking federal law. The FDA has explicitly addressed the “for research purposes only” disclaimer that some manufacturers use as a defence; in the Supreme Rejuvenation case the agency noted that the disclaimer does not change the regulatory analysis if there is no Investigational New Drug application in effect.

For an Australian reader, “FDA approved” is American shorthand for “an independent regulator has reviewed safety and efficacy and found a product fit to use.” That review has not happened anywhere in the world for any exosome product used in cosmetic indications.

How Australia regulates exosomes — and what most clinics don’t mention

The Therapeutic Goods Administration’s position is restrictive, but you will struggle to find it surfaced in clinic marketing copy.

Under the Therapeutic Goods Act 1989 and the Australian Regulatory Guidelines for Biologicals, products derived from human cells or tissue are regulated as biologicals. Biologicals cannot be supplied as cosmetics, sold over the counter, or marketed for cosmetic use without TGA assessment and inclusion on the Australian Register of Therapeutic Goods. The TGA’s September 2024 guidance on advertising stem cell and human cell or tissue products restates this in plain language.

No exosome product is currently registered on the ARTG for cosmetic indications. Plant-derived exosome-like particles in a topical serum sit in a different regulatory bucket and may be lawfully sold as cosmetic ingredients. Human-derived exosome products applied in a clinical setting do not, and the TGA has issued separate warnings about unapproved peptide and cell-derived products imported and used in Australian aesthetic settings.

How are Australian clinics offering them anyway? Usually by importing under various workarounds, by applying them topically (typically post-microneedling or post-laser, where there is a polite fiction that microscopic skin channels are “delivery” rather than “injection”), and sometimes by routing through compounding-pharmacy arrangements. None of this places the products inside the TGA’s assessment framework. The product you are paying for has not been reviewed by an Australian regulator.

When an Australian clinic offers you an exosome treatment, the relevant question is not whether exosomes are interesting. It is which exosome product, sourced from where, and supplied under what legal pathway.

What the published evidence shows on efficacy

The preclinical case for exosomes is genuinely strong. There is a deep literature on exosomes in wound healing, fibroblast activation, and inflammatory modulation. A 2022 systematic review identified 105 preclinical exosome wound-healing studies, with around half in animal models. Researchers working in this space are not inventing the mechanism; the laboratory science is real.

The clinical case for cosmetic skin use is much thinner. A small split-face study of exosomes combined with microneedling reported around a 32.5% improvement in acne scarring versus 19.9% for microneedling alone. Studies of adipose-derived stem-cell exosomes combined with microneedling have suggested wrinkle reduction in the order of 12% over a few months. A modest body of work on hair density has begun to accumulate. The 2024 Buzalaf JAAD review summarises the picture honestly: encouraging early signals, considerable methodological heterogeneity, small sample sizes, and limited follow-up.

What is missing is everything that turns a promising early signal into a settled treatment. Large randomised controlled trials. Long-term safety data. Head-to-head comparisons with cheaper, better-evidenced alternatives like platelet-rich plasma, plain microneedling, or topical retinoids. Standardisation of what counts as an “exosome product” across studies. The category is genuinely interesting at the bench. It is not yet, by the standards the rest of cosmetic medicine uses, an evidence-supported clinical treatment at the scale the marketing implies.

What the published evidence shows on complications

The complications literature has grown notably in 2024 and 2025, and it is the part of the picture most patients are not shown.

The Nahm and colleagues case series in Dermatological Reviews (July 2024, corrected February 2025) described seven women aged 26 to 37 in South Korea who developed delayed-onset granulomatous reactions after intradermal exosome treatment for skin rejuvenation. The lesions appeared two weeks to three months post-treatment. Histopathology in the biopsied case showed necrotising granulomas not related to mycobacterial infection. One of the cases in the series was from Australia. The authors recommended a one-month patch test in an inconspicuous area before any full-face application — which is not the message currently appearing in clinic marketing.

A JAAD Case Reports paper from April 2024 described a 50-year-old woman who developed multiple flesh-coloured papules and nodules on both cheeks seven weeks after a single exosome injection. The biopsy showed foreign-body granulomas.

Park and colleagues, in the Journal of Cosmetic Dermatology in October 2025, published a case series of four adult women who developed persistent erythema, nodules, granulomatous inflammation, and scarring following intradermal injection of exosome-containing products. Treatment required systemic and intralesional corticosteroids, laser therapy, and in some cases surgical removal. Most importantly, the outcomes section reports that all patients experienced incomplete resolution and residual scarring. The authors’ conclusion is the line worth sitting with: “Intradermal injection of unapproved exosome-based formulations may cause serious and persistent cutaneous complications. This case series underscores the need for regulatory enforcement, practitioner education, and public awareness to prevent off-label use.”

Tawanwongsri and colleagues, cited within the Park 2025 paper, described a case of skin necrosis following intradermal injection of a lyophilised exosome formulation, with histopathology showing both granulomatous inflammation and necrotic vascular changes. Yang and colleagues documented multiple foreign body granulomas after dermal injection of mesenchymal stem cell–conditioned media, illustrating a similar immune-mediated pattern.

The numbers, taken together, are still small — perhaps two dozen well-documented severe-complication cases in the published literature. They are also not zero, and they are accumulating in roughly the direction the regulatory authorities anticipated when they began warning about this category. The denominator (how many cosmetic exosome treatments have actually been performed worldwide) is unknown, and adverse-event reporting in Australian aesthetics is voluntary, which means published cases almost certainly understate the true incidence.

The bigger structural concern, flagged by reviewers in the 2024 JAAD review and reinforced by the 2025 Park case series, is the unknown. When the source, sterility, donor screening, and protein cargo of a clinic-administered exosome product are not characterised, the patient does not know what is being injected. Reviewers also note the theoretical risk that exosomes from the wrong tissue type can carry signals that promote cellular processes a patient would rather they did not. That is not a marketing claim. It is a published caveat from the people who study these particles for a living.

After any injectable cosmetic treatment, patients should contact their practitioner urgently if they experience sudden severe pain disproportionate to expected recovery, visual disturbance, blanching or mottling of the skin near the treatment area, fever, or rapidly spreading swelling. These can indicate vascular compromise, and the window for effective intervention is measured in hours, not days.

How regulators in adjacent markets have reacted

The international picture in the last eighteen months has shifted noticeably, and in one direction.

South Korea’s Ministry of Food and Drug Safety banned the term “exosome” in cosmetic advertising from 21 January 2025, on the explicit grounds that the word makes cosmetics sound like medicine and confuses consumers. Korea did not ban exosome science; it banned the marketing of cosmetics as if they were therapy. This is meaningful because Korea has been one of the most permissive markets globally for cosmetic injectables in recent years.

In the United Kingdom, The Guardian ran an investigation in March 2025 reporting that beauty clinics were openly offering treatments using human-derived exosomes that are unlawful under UK biologicals law. Cambridge experts quoted in the piece warned about the absence of donor screening and sterility oversight on the products being applied. A November 2025 undercover follow-up by ringing 50 UK clinics across Bristol, Cardiff, Glasgow, London, and Liverpool found multiple clinics openly offering human-derived exosome facials despite the regulatory status of those products.

The pattern across the four regulators is straightforward. The further regulators have looked, the more pushback they have applied. Australia has been quieter on this so far, but quietness is not the same as approval. The TGA’s classification of human-cell-derived material as a biological is unchanged. The absence of a public crackdown is not a green light. It is, more likely, lead time before one arrives.

What about topical exosome serums

A separate but related question. Exosome serums applied topically to the skin, often sold post-treatment by clinics or as standalone retail products, sit in a slightly different regulatory bucket but with the same fundamental concern.

The TGA distinguishes between cosmetic products (which influence appearance only and require no premarket review) and therapeutic goods (which influence physiology and require review). A topical product that makes purely cosmetic claims — “moisturises,” “smooths,” “brightens” — can be sold as a cosmetic. The moment a topical exosome product makes a structure-or-function claim — “regenerates skin,” “stimulates collagen,” “treats wrinkles” — it is legally classified as a therapeutic good and falls under the same review and biological-product requirements as the injectable version. The 2026 update to FDA guidance on exosome therapy makes this point explicit in the US context; the Australian framework is built on the same logic.

Virtually every exosome serum currently marketed in Australia makes some version of a structure-function claim. That places those products in a regulatory grey zone at best, and outside the framework at worst. The patient buying a $200 exosome serum from a clinic is buying a product that has not been reviewed by an Australian regulator for the use it is being marketed for.

What should I ask before booking an exosome treatment?

You do not need to be a cell biologist to ask useful questions. You do need to be willing to make a practitioner pause. The questions below are the ones most likely to identify whether a clinic is operating inside a regulatory framework or outside one.

What is the source of the exosomes in this product? Human stem cell, platelet, plant, animal, or bacterial? “Exosome” alone is not a complete answer; the source determines everything that follows.

Is the product registered on the Australian Register of Therapeutic Goods for the indication you are using? If not, what legal pathway is being used to supply it? A clinic that cannot answer this calmly and in detail is telling you something.

Has the manufacturer published characterisation data, sterility testing, and donor screening? Will they show you that documentation? Reputable products in any biological category have this information available; products operating outside the regulatory framework typically do not.

What is the published evidence base for this specific product, in this specific application, in humans? Brand-funded marketing decks do not count. A practitioner who cannot point you to peer-reviewed clinical evidence for the specific product they are using is not running a careful consultation.

What are the alternatives? Where do platelet-rich plasma, plain microneedling, polynucleotides, or topical retinoids sit in terms of evidence, cost, and risk for the same indication? A practitioner who reframes the conversation around what you are actually trying to achieve, rather than defending the specific product on the menu, is the practitioner you want.

A thoughtful, AHPRA-registered practitioner will welcome these questions and answer them honestly, including where the answer is “we do not fully know yet.” A defensive or hand-waving response is itself useful information.

The conservative summary

Exosomes are a real and genuinely interesting area of biological research. They are not, in 2026, a settled cosmetic treatment. The bench science is promising. The clinical evidence is thin. The regulatory direction of travel — the FDA’s repeated public safety notifications and growing warning-letter record, the TGA’s biologicals classification, Korea’s January 2025 advertising ban, the UK’s ongoing investigations — points unmistakably toward caution rather than permissiveness. The published complications literature has grown to include severe cases with permanent scarring, including in Australia.

That does not mean every clinic offering an exosome treatment is acting badly, and it does not mean every patient who has had one will have problems. It does mean that the gap between “interesting in the lab” and “safe and effective in your face” is wider than the marketing suggests, and that the responsibility for closing that gap sits with regulators, manufacturers, and practitioners — not with you.

If you are considering an exosome treatment, the most useful next step is to verify your practitioner on the AHPRA register at ahpra.gov.au, read the AHPRA consumer factsheet on cosmetic injectables, ask the questions described above, and treat the word “exosome” on a clinic menu the way you would treat any medical-sounding term being used as marketing copy. With curiosity and scepticism in equal measure. And if you are not certain, wait. The science is moving. The regulatory framework will catch up. The patient who decides to be early in this category is taking on risk the patient who waits a year or two will not have to.

References

FDA, Public Safety Notification on Exosome Products (current 2026). https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-products

FDA, Consumer Alert on Regenerative Medicine Products (22 July 2020). https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes

FDA Warning Letter: Supreme Rejuvenation LLC (5 May 2025). https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/supreme-rejuvenation-llc-700749-05052025

FDA Warning Letter: New Life Medical Services LLC (24 September 2025). https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/new-life-medical-services-llc-711102-09242025

FDA Warning Letter: Evolutionary Biologics Inc. (30 December 2024). https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/evolutionary-biologics-inc-681586-12302024

FDA Warning Letter: Neobiosis LLC (5 June 2024). https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/neobiosis-llc-662985-06052024

FDA Untitled Letter: Exocel Bio Inc. (7 May 2024). https://www.fda.gov/media/178528/download

TGA, Advertising stem cell and other human cell or tissue (HCT) products (updated 23 September 2024). https://www.tga.gov.au/resources/guidance/advertising-stem-cell-and-other-human-cell-or-tissue-hct-products

TGA, Understanding which therapeutic goods are regulated as biologicals. https://www.tga.gov.au/resources/guidance/understanding-which-therapeutic-goods-are-regulated-biologicals

AHPRA, Thinking about cosmetic injectables? Consumer factsheet. https://www.ahpra.gov.au/Resources/Cosmetic-surgery-hub/Information-for-the-public/Thinking-about-cosmetic-injectables.aspx

Park KY. Adverse Reactions Following Intradermal Injection of Exosome-Based Formulations: A Case Series. Journal of Cosmetic Dermatology, October 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12528963/

Nahm WJ et al. Complications After Exosome Treatment for Aesthetic Skin Rejuvenation. Dermatological Reviews, July 2024 (corrected February 2025). https://onlinelibrary.wiley.com/doi/10.1002/der2.242

Foreign body granuloma caused by injection of exosomes. JAAD Case Reports, April 2024. https://www.jaadcasereports.org/article/S2352-5126(24)00156-5/fulltext

Buzalaf MAR et al. Exploring the reality of exosomes in dermatology. Journal of the American Academy of Dermatology, 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11745280/

The Guardian. Beauty clinics in UK offering banned exosome treatments derived from human cells (29 March 2025). https://www.theguardian.com/society/2025/mar/29/beauty-clinics-uk-offering-banned-exosome-treatments-derived-human-cells

Important information

This article is provided for general educational purposes only and is not medical advice. It does not replace consultation with a registered medical practitioner. All cosmetic procedures carry risks. Outcomes vary between individuals. Suitability for any treatment is determined at a private consultation following clinical assessment, history-taking, and informed consent. If you are considering treatment, book a consultation with a registered medical practitioner.

If you are considering this procedure, the next step is a private consultation with a registered medical practitioner. Suitability is decided at consultation based on your clinical history, examination, and goals. Cosmabl’s mandatory consultation-and-cooling-off pathway applies to all procedures. Pricing is provided at consultation; we do not advertise time-limited prices, discounts, or package deals.

Many cosmetic procedures, prescription medications, and active skincare ingredients are contraindicated or have insufficient safety data in pregnancy and breastfeeding. If you are pregnant, planning pregnancy, or breastfeeding, discuss any treatment, prescription, or active-ingredient skincare with your GP, obstetrician, or registered medical practitioner before use.

Cosmabl (Northern Beaches Aesthetics Pty Ltd). Editorial governance POL-EDIT-001 v1.0; per-article record TPL-EDIT-001 v1.0. This article complies with the AHPRA / Medical Board Cosmetic Procedures Guidelines (effective 2 September 2025), the Therapeutic Goods Advertising Code, and section 133 of the Health Practitioner Regulation National Law.

Hero photo by Fernando Serrano on Pexels